PMS42 Cost-Utility of Tocilizumab Monotherapy in Methotrexate Intolerant/Contra-Indicated, Moderate/Severe Rheumatoid Arthritis Patients in Portugal
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1397
https://www.valueinhealthjournal.com/article/S1098-3015(12)03110-5/fulltext
Title :
PMS42 Cost-Utility of Tocilizumab Monotherapy in Methotrexate Intolerant/Contra-Indicated, Moderate/Severe Rheumatoid Arthritis Patients in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03110-5&doi=10.1016/j.jval.2012.08.1397
First page :
A447
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
894